| Barry Isaac Davenport, MD | |
|
301 N 1st St Bldg 46, Altus, OK 73523-5004 | |
| (580) 481-5230 | |
| Not Available |
| Full Name | Barry Isaac Davenport |
|---|---|
| Gender | Male |
| Speciality | Emergency Medicine |
| Experience | 5 Years |
| Location | 301 N 1st St Bldg 46, Altus, Oklahoma |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1912468042 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2083A0100X | Preventive Medicine - Aerospace Medicine | 37355 (Oklahoma) | Primary |
| 207P00000X | Emergency Medicine | S9125 (Texas) | Secondary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Mangum Regional Medical Center | Mangum, OK | Hospital |
| Wilbarger General Hospital | Vernon, TX | Hospital |
| Alliancehealth Woodward | Woodward, OK | Hospital |
| Newman Memorial Hospital | Shattuck, OK | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Concord Medical Group Of Texas Pllc | 7810117223 | 252 |
| Ess Of South Texas Llc | 9739491176 | 14 |
| Mangum City Hospital Authority | 6305119942 | 10 |
| Newman Memorial Hospital, Inc | 2567482367 | 17 |
News Archive
Experiments using fruit flies have helped a team at the MRC National Institute for Medical Research to identify genes that control how large the developing brain becomes.
A new EEG study conducted on college students at American University found they could more highly activate the default mode network, a suggested natural "ground state" of the brain, during their practice of the Transcendental Meditation technique. This three-month randomized control study is published in a special issue of Cognitive Processing dedicated to the Neuroscience of Meditation and Consciousness, Volume 11, Number 1, February, 2010.
A new therapy that reduces the risk of mortality and heart failure in patients with mild cardiac disease received a thumb's up this week from an advisory panel to the U.S. Food and Drug Administration. The panel recommended that the cardiac resynchronization therapy defibrillator (CRT-D), tested extensively nationwide under the leadership of cardiologist Arthur Moss, M.D., professor of Medicine at the University of Rochester Medical Center, be approved for use in patients with mild heart failure in the United States.
Genta Incorporated today announced top-line results from AGENDA, the Company's Phase 3 trial of Genasense® (oblimersen sodium) Injection in patients with advanced melanoma. AGENDA is a randomized, double-blind, placebo-controlled trial of dacarbazine administered with or without Genasense® in patients who have not previously received chemotherapy.
› Verified 2 days ago
| Entity Name | Concord Medical Group Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1083630610 PECOS PAC ID: 0446296818 Enrollment ID: O20050707000531 |
News Archive
Experiments using fruit flies have helped a team at the MRC National Institute for Medical Research to identify genes that control how large the developing brain becomes.
A new EEG study conducted on college students at American University found they could more highly activate the default mode network, a suggested natural "ground state" of the brain, during their practice of the Transcendental Meditation technique. This three-month randomized control study is published in a special issue of Cognitive Processing dedicated to the Neuroscience of Meditation and Consciousness, Volume 11, Number 1, February, 2010.
A new therapy that reduces the risk of mortality and heart failure in patients with mild cardiac disease received a thumb's up this week from an advisory panel to the U.S. Food and Drug Administration. The panel recommended that the cardiac resynchronization therapy defibrillator (CRT-D), tested extensively nationwide under the leadership of cardiologist Arthur Moss, M.D., professor of Medicine at the University of Rochester Medical Center, be approved for use in patients with mild heart failure in the United States.
Genta Incorporated today announced top-line results from AGENDA, the Company's Phase 3 trial of Genasense® (oblimersen sodium) Injection in patients with advanced melanoma. AGENDA is a randomized, double-blind, placebo-controlled trial of dacarbazine administered with or without Genasense® in patients who have not previously received chemotherapy.
› Verified 2 days ago
| Entity Name | Concord Medical Group Of Texas Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1750790762 PECOS PAC ID: 7810117223 Enrollment ID: O20141007002567 |
News Archive
Experiments using fruit flies have helped a team at the MRC National Institute for Medical Research to identify genes that control how large the developing brain becomes.
A new EEG study conducted on college students at American University found they could more highly activate the default mode network, a suggested natural "ground state" of the brain, during their practice of the Transcendental Meditation technique. This three-month randomized control study is published in a special issue of Cognitive Processing dedicated to the Neuroscience of Meditation and Consciousness, Volume 11, Number 1, February, 2010.
A new therapy that reduces the risk of mortality and heart failure in patients with mild cardiac disease received a thumb's up this week from an advisory panel to the U.S. Food and Drug Administration. The panel recommended that the cardiac resynchronization therapy defibrillator (CRT-D), tested extensively nationwide under the leadership of cardiologist Arthur Moss, M.D., professor of Medicine at the University of Rochester Medical Center, be approved for use in patients with mild heart failure in the United States.
Genta Incorporated today announced top-line results from AGENDA, the Company's Phase 3 trial of Genasense® (oblimersen sodium) Injection in patients with advanced melanoma. AGENDA is a randomized, double-blind, placebo-controlled trial of dacarbazine administered with or without Genasense® in patients who have not previously received chemotherapy.
› Verified 2 days ago
| Entity Name | Ess Of South Texas Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1295128247 PECOS PAC ID: 9739491176 Enrollment ID: O20150629000248 |
News Archive
Experiments using fruit flies have helped a team at the MRC National Institute for Medical Research to identify genes that control how large the developing brain becomes.
A new EEG study conducted on college students at American University found they could more highly activate the default mode network, a suggested natural "ground state" of the brain, during their practice of the Transcendental Meditation technique. This three-month randomized control study is published in a special issue of Cognitive Processing dedicated to the Neuroscience of Meditation and Consciousness, Volume 11, Number 1, February, 2010.
A new therapy that reduces the risk of mortality and heart failure in patients with mild cardiac disease received a thumb's up this week from an advisory panel to the U.S. Food and Drug Administration. The panel recommended that the cardiac resynchronization therapy defibrillator (CRT-D), tested extensively nationwide under the leadership of cardiologist Arthur Moss, M.D., professor of Medicine at the University of Rochester Medical Center, be approved for use in patients with mild heart failure in the United States.
Genta Incorporated today announced top-line results from AGENDA, the Company's Phase 3 trial of Genasense® (oblimersen sodium) Injection in patients with advanced melanoma. AGENDA is a randomized, double-blind, placebo-controlled trial of dacarbazine administered with or without Genasense® in patients who have not previously received chemotherapy.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Barry Isaac Davenport, MD 301 N 1st St Bldg 46, Altus, OK 73523-5004 Ph: (580) 481-5230 | Barry Isaac Davenport, MD 301 N 1st St Bldg 46, Altus, OK 73523-5004 Ph: (580) 481-5230 |
News Archive
Experiments using fruit flies have helped a team at the MRC National Institute for Medical Research to identify genes that control how large the developing brain becomes.
A new EEG study conducted on college students at American University found they could more highly activate the default mode network, a suggested natural "ground state" of the brain, during their practice of the Transcendental Meditation technique. This three-month randomized control study is published in a special issue of Cognitive Processing dedicated to the Neuroscience of Meditation and Consciousness, Volume 11, Number 1, February, 2010.
A new therapy that reduces the risk of mortality and heart failure in patients with mild cardiac disease received a thumb's up this week from an advisory panel to the U.S. Food and Drug Administration. The panel recommended that the cardiac resynchronization therapy defibrillator (CRT-D), tested extensively nationwide under the leadership of cardiologist Arthur Moss, M.D., professor of Medicine at the University of Rochester Medical Center, be approved for use in patients with mild heart failure in the United States.
Genta Incorporated today announced top-line results from AGENDA, the Company's Phase 3 trial of Genasense® (oblimersen sodium) Injection in patients with advanced melanoma. AGENDA is a randomized, double-blind, placebo-controlled trial of dacarbazine administered with or without Genasense® in patients who have not previously received chemotherapy.
› Verified 2 days ago